Cullinan Oncology to Participate in Upcoming Investor Conferences
31 Luglio 2023 - 2:00PM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a
biopharmaceutical company focused on modality-agnostic targeted
oncology therapies, today announced its participation in the
following upcoming investor conferences:
- Nadim Ahmed, Chief Executive Officer, will participate in a
fireside chat at the BTIG Virtual Biotechnology Conference 2023 on
Monday, August 7, 2023 at 10:30 a.m. EDT
- Cullinan’s management team will be hosting 1-on-1 meetings at
the 2023 Wedbush PacGrow Healthcare Conference in New York, NY on
Tuesday, August 8, 2023
BTIG-hosted events are intended for prospective and existing
BTIG clients only. To listen to the live event, please contact your
BTIG representative.
About Cullinan Oncology Cullinan Oncology,
Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated
to creating new standards of care for patients with cancer. We
innovate without borders to find the most promising clinic-ready
cancer therapies, whether from our own discovery efforts or through
exceptional engagement with our academic and industry partners.
Anchored in a deep understanding of immuno-oncology and
translational cancer medicine, we leverage our scientific
excellence in small molecules and biologics to create
differentiated ideas, identify unique targets, and select the
optimal modality to develop transformative therapeutics across
cancer indications. Powered by our novel research model, we push
conventional boundaries from candidate selection to cancer
therapeutic, applying rigorous early experimentation to fast-track
only the most promising assets to the clinic and ultimately
commercialization. As a result, our diversified pipeline is
strategically built with assets that activate the immune system or
inhibit key oncogenic drivers across a wide range of modalities,
each with the potential to be the best or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Contacts: Investor Relations Chad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1 215.801.7644rweldon@cullinanoncology.com
Grafico Azioni Cullinan Therapeutics (NASDAQ:CGEM)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Cullinan Therapeutics (NASDAQ:CGEM)
Storico
Da Mag 2023 a Mag 2024